To help MaRS build great companies from Canadian technology and ingenuity, John advises clients with therapeutic innovations. He leads the MaRS Future of Medicine™ conferences and discussion series and contributes to commercial development by working closely with aligned organizations such as MaRs Innovation. For more than 15 years, John has advised life sciences investors and evaluated clinical, regulatory, intellectual property and competitive issues in North America, the EU and Japan. He is also an active fundraiser for the Centre for Addiction and Mental Health Foundation.

“I’m passionate about ensuring that the great assets we have in the research community are realized for the common good. When nascent companies get access to stuff that would otherwise be out of reach, and when we help them avoid mistakes that could be fatal—it’s fantastic!”

Highlights

• Aggregate Therapeutics, President and COO
• Drug Royalty Corporation, Vice President, Medical and Scientific Affairs
• University of London, PhD